IL1B and breast carcinoma: This rationale is also strengthened by results from preclinical models, in which combination of anti-IL-1β blocking antibodies with programmed cell death protein 1 (PD-1) blockade exhibited significantly improved tumor control and overall survival of mice in murine breast cancer models [51].